Markets
ProKidney Corp. (PROK)
PROKNASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$1.05
-0.1100 (-9.52%) today
Closed, Nov 13, 4:00 PM ET
-9.52% 1D
- Market cap
- $315.99m
- P/E
- –
- EPS, last 4 quarters
- $-0.6000
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.8702 to $2.66
- Average volume
- –
- Previous close
- $1.16
Analysts
5 coveringBuy2 buy, 2 hold, 1 sell
Targets a year out average $10.00, +856.9% from here
$8.00now $1.05$12.00
Earnings
next estimate $-0.1100Next report
Dec 2025
+12.5%
Mar 2026
-7.7%
Jun 2026
-15.4%
Sep 2026
-30.8%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $225.0k | $226.0k | $150.0k | $174.0k |
| Gross profit | $225.0k | $226.0k | $150.0k | $174.0k |
| Operating income | -$45.37m | -$44.93m | -$48.37m | -$53.76m |
| Net income | -$19.23m | -$20.04m | -$28.42m | -$35.59m |
Last four quarters: revenue $775.0k, margin -13326.7%, free cash flow -$167.83m
News
8 latest- ProKidney Corp. Reports Third Quarter 2026 Financial Results and Business HighlightsFintel · 13 hours ago
- ProKidney Corp. (PROK) Reports Q3 Loss, Misses Revenue EstimatesZacks · 1 day ago
- Merck KGaA (MKKGY) Lags Q3 Earnings EstimatesZacks · 1 day ago
- ProKidney Corp. Reports $141.9 million in Cash and Outlines Phase 3 PROACT 1 MilestonesFintel · 5 days ago
- Aclaris Therapeutics (ACRS) Reports Q3 Loss, Beats Revenue EstimatesZacks · Nov 5, 2026
- ProKidney Corp. Enters into $200,000,000 Open Market Sale Agreement with Jefferies LLCFintel · Nov 2, 2026
- ProKidney Targets Q2 2027 Phase III Readout as Rilparencel Enrollment Surpasses 500MarketBeat · Oct 28, 2026
- ProKidney Consensus Price Target Raised by 10.40% to $7.04Fintel · Oct 23, 2026
The company
ProKidney is developing rilparencel for patients with Stage 3b/4 CKD and diabetes, a population that includes over one million people in the...
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- prokidney.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.